Blueteq News
HSE Approves Skyclarys (Omaveloxolone) for Friedreich’s Ataxia
n 25 August 2026 the HSE Senior Management Team approved the reimbursement of omaveloxolone (Skyclarys®, Biogen) for patients with Friedreich’s Ataxia, a rare progressive neurological
Prescribed List Update — New Medicines from 1 September 2026
Social Security Minister Elaine Millar approved changes to Jersey’s Prescribed List with effect from 1 September 2026, following recommendations from the Pharmaceutical Benefit Advisory Committee.
Northern Ireland – August Blueteq Brief
New Health Minister Appointed Mr Robbie Butler was appointed Minister of Health for Northern Ireland on 20 August 2026, replacing his predecessor in the role.
SMC Decisions — 10 August 2026
The Scottish Medicines Consortium published advice on seven medicines on 10 August 2026. All seven were accepted: Blueteq comment:. Almost all would typically sit on Blueteq prior-approval forms in England,
NICE Technology Appraisals — August 2026
On 6 August 2026, NICE recommended acalabrutinib (Calquence®, AstraZeneca) in two combination regimens for first-line treatment of blood cancers. Acalabrutinib plus bendamustine and rituximab was
NCPE — First National HTA Using EU Joint Clinical Assessment Data
The NCPE completed a rapid review of onasemnogene abeparvovec intrathecal (Itvisma®), Novartis’s intrathecal gene therapy for spinal muscular atrophy (SMA), making this the first national
